01·Encyclopedia
75 hero peptides
From BPC-157 to Tirzepatide, with mechanism, half-life, route, legal status, and the trials behind every claim — all on one page per compound.
Browse the encyclopedia
Educational only. Not medical advice. Consult a qualified clinician before any peptide use.
A verified source
Peptides, without the influencer hype.
Every claim on this site routes back to a primary source. No appeals to authority. No vendor links. Just the research, the mechanisms, and the protocols — graded for the strength of the evidence behind them.
- Peptides indexed
- 75
- Primary sources
- 221
- Mechanisms covered
- 143
01·Inside the corpus
The dossier, in numbers.
Every claim routes to a primary source. Every source is graded for provenance and tagged for the strength of the evidence it carries. Every peptide has its own dated monograph. The library is structured, dated, and growing.
a·Evidence tier mix
Every source is graded on a four-tier scale (peer-primary → practitioner). Tier-1 is the load-bearing layer: 143 of 221 (65%).
- T1· Peer-primary14365%
- T2· Peer-secondary6228%
- T3· Expert-primary167%
- T4· Practitioner00%
b·Source-type mix
What the corpus is actually made of. Reviews and mechanistic work outweigh RCT count because the underlying field is receptor-biology heavy, with selective clinical-trial coverage.
- RCT92
- Mechanistic64
- Review26
- Cohort25
- Meta-analysis10
- Opinion3
- Case report1
- Journals represented
- 138
- Year span
- 1963–2026
- 63 years
- Source links
- 249
- 3.3 avg / peptide
- Mechanisms covered
- 143
c·Most recent reviewed additions
- 01Lanreotide in metastatic enteropancreatic neuroendocrine tumorsCaplin ME, Pavel M, Ćwikła JB, et al. · 2014 · New England Journal of Medicine·reviewed 2026-05-19T1
- 02Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedemaCicardi M, Banerji A, Bracho F, et al. · 2010 · New England Journal of Medicine·reviewed 2026-05-19T1
- 03Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaFacon T, Kumar S, Plesner T, et al. · 2019 · New England Journal of Medicine·reviewed 2026-05-19T1
- Vendor links
- 0
- Affiliate codes
- 0
- Sponsored content
- 0
- Claims without a source
- 0
02·What lives here
02·Research
Tier-graded sources
Every paper labelled Tier 1–4 (peer-primary → practitioner) and tagged with a strength score (strong / moderate / suggestive / anecdotal). No editorial inflation.
Open the library
03·Critic
Influencer claims, fact-checked
What a podcast said, lined up against what the literature actually shows — with the parts the critic got right surfaced honestly alongside the parts they did not.
Read the responses
03·The registry — built from structured cycle data
Most peptide self-experimenters run their cycles alone. The reports that exist sit scattered across Reddit threads, podcast comments, and private notebooks. This site is the structured alternative: editorial protocols anchored in the published literature, plus community-reported and member-logged cycles with disciplined provenance separation. The aggregate is the moat.
- Total cycles in registry
- 51
- Editorial protocols
- 39
- Synthesized from published trials
- Member-logged
- 0
- Consented to aggregate
A·Contribute
Add an N=1 to the registry.
Anonymous by default. No account required. Verified by email, reviewed by an editor before it appears.
Submit a cycle
B·See the aggregate
Members see the data sliced by peptide.
Paired baseline ↔ post-cycle biomarker deltas, adverse-event incidence by class, dose-response patterns. All enforced k≥5.
See membership
Launching July 2026
Get the founders list.
75 peptide briefings before launch and the free 6-page PDF — Top 10 Peptides Worth Knowing — delivered to your inbox the moment you confirm the address.
One unsubscribe click ends it forever. The address is never sold and never shared with vendors.